Efficacy and safety of the direct switch to indacaterol/glycopyrronium from salmeterol/fluticasone in non-frequently exacerbating COPD patients: The FLASH randomized controlled trial.
Peter A FrithSamiha AshmawiSrikanth KrishnamurthyAlev GurgunSashka HristoskovaVirginia PilipovicAnna Marie HamannArthur BackerPetter OlssonKonstantinos KostikasDina V Diaznull nullPublished in: Respirology (Carlton, Vic.) (2018)
FLASH demonstrated that a direct switch to IND/GLY from SFC improved pre-dose FEV1 and FVC in COPD patients with up to one exacerbation in the previous year. No new safety signals were identified.